ENTITY
Shanghai Henlius Biotech

Shanghai Henlius Biotech (2696 HK)

109
Analysis
Health CareChina
Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.
more
Refresh
23 May 2024 14:40

Henlius Biotech (2696 HK): Fosun Offer?

IF Fosun wants to take the company private, an Offer Price of $26/share, may get the job done. $30/share would be optically be more preferable.

Logo
347 Views
Share
bullishAlps Logistics
06 Aug 2024 10:09

Go-To Arbs Amid Market Carnage

As global market roil, clean M&A deals come into focus. This insight briefly summarises those deals which are expected to comfortably complete,...

Logo
463 Views
Share
bullishFancl Corp
03 Aug 2024 15:00

(Mostly) Asia-Pac M&A:Ansarada, Southern Cross Gold, A8 New Media, CPMC, Mandala Multifinance, Fancl

This insight provides a summary of gross/annualised spreads (on deals discussed on Smartkarma) across Asia-Pacific as at the last trading date, and...

Logo
356 Views
Share
bullishArvida
01 Aug 2024 07:00

(Mostly) Asia M&A, July 2024: Canvest, Furukawa, Arvida, Advanced Info, Sermsuk, Thaicom

The average premium for the new transactions announced (or first discussed) in July was ~31%. The average premium YTD is ~44%.

Logo
314 Views
Share
29 Jul 2024 00:42

Merger Arb Mondays (29 Jul) - China TCM, Canvest, CPMC, GA Pack, Tohokushinsha, Furukawa, Tatsuta

This week, the highest gross spreads are HEC Pharma (126.8%), China TCM (37.3%), Canvest (11.9%), GAPack (11.8%), Asia Cement China (10.7%),...

Logo
430 Views
Share
x